Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Euronext N.V.. (10/8/18). "Press Release: Medincell Lists on Euronext Paris. €30 Million Raised, Market Capitalisation €144 Million". Paris.

Region Region France
Organisations Organisation Euronext Paris S.A.
  Group Euronext (Group)
  Organisation 2 MedinCell S.A. (Euronext: MEDCL)
  Group MedinCell (Group)
Products Product BEPO® technology
  Product 2 investment banking
Index term Index term MedinCell–SEVERAL: investment, 201810 IPO €30m with 4.14m new shares at €7.25m/share at Euronext Paris
Person Person Douat, Christophe (MedinCell 201810 Board Chairman)

Euronext today welcomed MedinCell, a pharmaceutical technology company that develops injectable drug delivery solutions, to listing in compartment C of Euronext Paris.

Based in Jacou, near Montpellier in southern France, MedinCell is dedicated to achieving significant gains in the efficiency of drug therapies. The two most advanced products in its pipeline, designed to treat schizophrenia and post-operative orthopedic pain, respectively, are now in Phase III and Phase II clinical trials in the United States. Its seven other products treat a range of conditions including depression, chronic pain and contraception—all areas where MedinCell’s patented BEPO® technology is likely to change conditions fundamentally.

MedinCell (ticker code: MEDCL) was listed on 8 October 2018 through the admission to trading of 19,878,372 shares making up its capital, including 4,137,931 new shares issued through a Global Offering[1] before potential exercise of the over-allotment option and 1,258,841 shares issued in exchange for convertible bonds.

The offering price was set at €7.25 per share. Market capitalisation on the day of listing was around €144 million, and the operation raised a total of €30 million.

At the listing ceremony, Christophe Douat, Chairman of MedinCell’s Executive Board, said: “Today’s listing is a milestone for MedinCell. It confirms the expertise and tenacity of the entire MedinCell team, and illustrates the strength of our approach, in which all of our staff members are either already shareholders or will have that opportunity. This is one key to our success—a success that includes two products already in Phase II and III clinical trials in the United States, with ten more in the pipeline. The funds we’ve raised will enable us to expand our portfolio and increase our impact on global health. I would like to take this opportunity to thank all our team members who have been working hard to this end, as well as the new shareholders who have joined us and who share our goals, including our vision of harnessing pharmaceuticals to serve human well-being, and our commitment to a better world.”

[1] The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) in France and a Global Placement with institutional investors in France and other countries.

About MedinCell

MedinCell is a pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients that are already known and marketed. Based on controlled, long-acting release of active pharmaceutical ingredients, MedinCell makes medical treatments more efficient by improving patient adherence to medical prescriptions and by significantly reducing the quantity of medication required to treat one-off and chronic conditions. BEPO® technology ensures consistent, reliable delivery of a drug at the optimum therapeutic dose for several days, weeks or months, starting from a small subcutaneous or local injection and deposit that is fully bioresorbable. Based in Montpellier, MedinCell currently employs approximately 100 people representinq over 25 different nationalities.

About Euronext

Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.9 trillion in market capitalisation as of end September 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index? and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.

For the latest news, find us on Twitter ( and LinkedIn (


This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

Record changed: 2019-12-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for Euronext (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top